Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA, USA.
Cancer Biol Ther. 2012 Oct;13(12):1205-13. doi: 10.4161/cbt.21353. Epub 2012 Aug 15.
To determine whether the spheroid culture can be used to evaluate drug efficacy, we have evaluated the toxicity of free or carrier-associated doxorubicin as a single drug or in combination with other antineoplastic agents using the spheroid cultures of drug-resistant cancer cells. Paclitaxel, cisplatin, dexamethasone, mitoxantrone, sclareol or methotrexate were used in combination with doxorubicin. The effect of the treatment protocols on free, micellar and liposomal doxorubicin accumulation in spheroids and on resulting toxicity was evaluated by fluorescence and lactate dehydrogenase release, respectively. Enhanced doxorubicin accumulation and toxicity were observed after spheroid pretreatment with mitoxantrone or paclitaxel. Effects of the drug combination with doxorubicin were sequence dependent, use of doxorubicin as the first drug being the least inducer of toxicity. Finally, spheroids were recognized by a cancer cell-specific antibody. Our results suggest the usefulness of spheroids to evaluate chemotherapy combinations.
为了确定球体培养是否可用于评估药物疗效,我们使用耐药癌细胞的球体培养物评估了游离或载体结合的阿霉素作为单一药物或与其他抗肿瘤药物联合使用的毒性。紫杉醇、顺铂、地塞米松、米托蒽醌、青蒿醇或甲氨蝶呤与阿霉素联合使用。通过荧光和乳酸脱氢酶释放分别评估治疗方案对球体中游离、胶束和脂质体阿霉素积累以及由此产生的毒性的影响。在用米托蒽醌或紫杉醇预处理球体后,观察到阿霉素的积累和毒性增强。药物组合与阿霉素的作用具有序列依赖性,将阿霉素作为第一种药物使用时毒性最小。最后,用一种癌细胞特异性抗体识别球体。我们的结果表明,球体可用于评估化疗组合。